WO2001039573A3 - Verwendung von lungensurfactant zur behandlung von legionärskrankheit - Google Patents

Verwendung von lungensurfactant zur behandlung von legionärskrankheit Download PDF

Info

Publication number
WO2001039573A3
WO2001039573A3 PCT/EP2000/012012 EP0012012W WO0139573A3 WO 2001039573 A3 WO2001039573 A3 WO 2001039573A3 EP 0012012 W EP0012012 W EP 0012012W WO 0139573 A3 WO0139573 A3 WO 0139573A3
Authority
WO
WIPO (PCT)
Prior art keywords
legionnaire
disease
treating
novel use
lung surfactant
Prior art date
Application number
PCT/EP2000/012012
Other languages
English (en)
French (fr)
Other versions
WO2001039573A2 (de
Inventor
Rolf-Peter Hummel
Peter Schaffer
Original Assignee
Byk Gulden Lomberg Chem Fab
Hummel Rolf Peter
Peter Schaffer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab, Hummel Rolf Peter, Peter Schaffer filed Critical Byk Gulden Lomberg Chem Fab
Priority to AU20032/01A priority Critical patent/AU2003201A/en
Publication of WO2001039573A2 publication Critical patent/WO2001039573A2/de
Publication of WO2001039573A3 publication Critical patent/WO2001039573A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die Erfindung beschreibt die neue Verwendung von Lungensurfactant-Zubereitungen zur Behandlung der Legionärskrankheit.
PCT/EP2000/012012 1999-12-01 2000-11-30 Verwendung von lungensurfactant zur behandlung von legionärskrankheit WO2001039573A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20032/01A AU2003201A (en) 1999-12-01 2000-11-30 Novel use of lung surfactant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99123800.7 1999-12-01
EP99123800 1999-12-01

Publications (2)

Publication Number Publication Date
WO2001039573A2 WO2001039573A2 (de) 2001-06-07
WO2001039573A3 true WO2001039573A3 (de) 2002-04-11

Family

ID=8239501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/012012 WO2001039573A2 (de) 1999-12-01 2000-11-30 Verwendung von lungensurfactant zur behandlung von legionärskrankheit

Country Status (2)

Country Link
AU (1) AU2003201A (de)
WO (1) WO2001039573A2 (de)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0215562A1 (de) * 1985-08-06 1987-03-25 Albright & Wilson Limited Biozide Zusammensetzungund Verfahren zur Behandlung von Wasser
EP0291488A2 (de) * 1987-05-12 1988-11-17 Pharmacin Corporation Erythromycin-Derivate und ihre Herstellung und Verwendung
WO1991000871A1 (en) * 1989-07-11 1991-01-24 Genentech, Inc. Surfactant compositions and methods
EP0538011A1 (de) * 1991-10-16 1993-04-21 Schering Corporation Lipophile Zusammensetzungen von Oligosaccharid-Antibiotikasalzen
WO1993021221A1 (en) * 1992-04-10 1993-10-28 Abbott Laboratories Pulmonary surfactant protein fragments
WO1995032992A1 (de) * 1994-05-31 1995-12-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Synthetische peptidanaloge des lungenoberflächenproteins sp-c
WO1998049191A1 (en) * 1997-04-28 1998-11-05 The Scripps Research Institute Novel pulmonary surfactants and therapeutic uses, including pulmonary lavage

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0215562A1 (de) * 1985-08-06 1987-03-25 Albright & Wilson Limited Biozide Zusammensetzungund Verfahren zur Behandlung von Wasser
EP0291488A2 (de) * 1987-05-12 1988-11-17 Pharmacin Corporation Erythromycin-Derivate und ihre Herstellung und Verwendung
WO1991000871A1 (en) * 1989-07-11 1991-01-24 Genentech, Inc. Surfactant compositions and methods
EP0538011A1 (de) * 1991-10-16 1993-04-21 Schering Corporation Lipophile Zusammensetzungen von Oligosaccharid-Antibiotikasalzen
WO1993021221A1 (en) * 1992-04-10 1993-10-28 Abbott Laboratories Pulmonary surfactant protein fragments
WO1995032992A1 (de) * 1994-05-31 1995-12-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Synthetische peptidanaloge des lungenoberflächenproteins sp-c
WO1998049191A1 (en) * 1997-04-28 1998-11-05 The Scripps Research Institute Novel pulmonary surfactants and therapeutic uses, including pulmonary lavage

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LACZIKA, K. ET AL: "Tremendous high plasma lipopolysaccharide concentrations in a patient with Legionella pneumophilia pneumonia", JOURNAL OF ENDOTOXIN RESEARCH, vol. 4, no. 4, 1997, pages 301 - 304, XP000925672 *
NEUMEISTER, B. ET AL: "Effects of different surfactant preparations on bacteerial growth in vitro", BIOLOGY OF THE NEONATE, vol. 70, no. 2, 1996, pages 128 - 134, XP000925564 *

Also Published As

Publication number Publication date
AU2003201A (en) 2001-06-12
WO2001039573A2 (de) 2001-06-07

Similar Documents

Publication Publication Date Title
EP1491542A3 (de) Zwischenprodukte
AU5242000A (en) Nematicidal trifluorobutenes
ZA200404306B (en) 3'-prodrugs of 2'-deoxy-beta-L-nucleosides.
WO2001066564A3 (en) Gamma-secretase inhibitors
AU2001273132A1 (en) Compounds to treat alzheimer's disease
WO2002002505A3 (en) Compounds to treat alzheimer's disease
WO2002002512A3 (en) Compounds to treat alzheimer's disease
CA2278201A1 (en) Novel modifications to 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonyl-aminobenzene, and processes for their preparation
HUP0002956A3 (en) Use of 4-aminopyrrole[3,2d]pyrimidines for the preparation of pharmaceutical compositions treating diseases related to an excess of neuropeptide y
HK1037861A1 (en) Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
AU6083899A (en) Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
CA2362698A1 (en) Resorcinol derivatives
AU2021601A (en) Composition for the treatment of dandruff
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
AU2001265876A1 (en) Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
WO2001039573A3 (de) Verwendung von lungensurfactant zur behandlung von legionärskrankheit
AU4225500A (en) Methods and compositions for the treatment and prevention of lung disease
ZA200102818B (en) Process for the preparation of 4,4'-dihalogen-O-hydroxydiphenyl compounds.
HK1041606B (zh) N，n'-羰基雙內酰胺的製備方法
ITMI992457A0 (it) Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidrois ochinolin-3-carbossiammide
AU2002239505A1 (en) Methods and compositions for the diagnosis and treatment of viral disease using 55092

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BG BR CA CN CZ EE GE HR HU ID IL IN JP KR LT LV MK MX NO NZ PL RO SG SI SK UA US VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BG BR CA CN CZ EE GE HR HU ID IL IN JP KR LT LV MK MX NO NZ PL RO SG SI SK UA US VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP